Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
La Jolla Pharmaceutical Company |
---|---|
Information provided by: | La Jolla Pharmaceutical Company |
ClinicalTrials.gov Identifier: | NCT00089804 |
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
Condition | Intervention | Phase |
---|---|---|
Lupus Erythematosus, Systemic Lupus Nephritis |
Drug: abetimus sodium (LJP 394) and/or placebo solution Drug: abetimus sodium (LJP 394) Drug: Phosphate-buffered saline |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease |
Estimated Enrollment: | 730 |
Study Start Date: | October 2004 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
|
Drug: abetimus sodium (LJP 394) and/or placebo solution
300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
|
2: Active Comparator
900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
|
Drug: abetimus sodium (LJP 394)
900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
|
3: Placebo Comparator
A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
|
Drug: Phosphate-buffered saline
A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
|
Ages Eligible for Study: | 12 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Michael J Tansey, MD | 858-452-6600 |
Study Director: | Michael J Tansey, MD, Ph.D. | Chief Medical Officer, La Jolla Pharmaceutical Company |
Responsible Party: | La Jolla Pharmaceutical Company ( Michael J. Tansey, Chief Medical Officer ) |
Study ID Numbers: | LJP 394-90-14 |
Study First Received: | August 13, 2004 |
Last Updated: | December 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00089804 |
Health Authority: | United States: Food and Drug Administration |
Lupus Nephritis Kidney |
SLE Systemic Lupus Erythematosus Nephritis, Lupus |
Glomerulonephritis Autoimmune Diseases Urologic Diseases Lupus Erythematosus, Systemic |
Lupus Nephritis Nephritis Connective Tissue Diseases Kidney Diseases |
Immune System Diseases |